atepeq/tico19 huggingface dataset:
The study of CoVs in bats and other animals has drastically changed our perception of the importance of zoonotic origins and animal reservoirs of HCoVs in human transmission.
Boyekoli ya CoVs na bangembo mpe na banyama mosusu ebongoli mpenza ndenge na biso ya kotalela kondima soki HCoVs euta na banyama mpe banyama oyo ebombaka yango liboso epesa yango na bato.
Pervasive evidence has shown that SARS-CoV, MERS-CoV and SARS-CoV-2 have a bat origin and are transmitted to humans via intermediate hosts.
Bilembeteli ya solo te emonisi ete SARS-CoV, MERS-CoV mpe SARS-CoV-2 euta na ngembo mpe ekotaka na bato na nzela ya biloko mosusu oyo ebombaka yango.
Given that SARS-CoV infection originates from the contact between humans and civets in the markets, closing wet markets and killing civets therein could have effectively ended the SARS epidemic.
Mpo maladi ya SARS-CoV euti na bokutani kati na bato mpe ba civet na bazando, kokanga bazando ya banyama ya mobesu mpe koboma ba civet oyo eza kuna ekokoki kosukisa maladi ya SARS.
By the same reasoning, pangolins should be removed from wet markets to prevent zoonotic transmission, in view of the discovery of multiple lineages of pangolin beta-CoVs closely related to SARS-CoV-2.
Na makanisi moko wana, basengeli kolongola bapangolin na bazando ya banyama ya mobesu mpo na kokanga nzela ete banyama epesa biso te maladi wana, mpo makambo mingi emonisi ete ba beta-CoVs mingi oyo euti na pangolin ezali na boyokani na SARS-CoV-2.
However, whether and how SARS-CoV-2 is transmitted to humans through pangolins and other mammals remain to be clarified in future investigations.
Kasi, bolukiluki oyo ekosalema na mokilo ezali koya ekosalisa na koyeba soki bato bazwaki mpenza SARS-CoV-2 na bapangolin mpe banyama mosusu.
On the other hand, MERS-CoV has existed in dromedary camels for a long time.
Na ndambo mosusu, MERS-CoV ekotela bakamela dromadaire banda kala.
These camels serve as an important tool for transportation as well as a main source of meat, milk, leather and wool products for the local people.
Bakamela bazali na mokumba ya ntina mpo na komema maladi wana na bato, lolenge moko na misuni, miliki, mposo ya nyama mpe biloko ya laine mpona bato ya mboka.
They are widely distributed across the Middle East and Africa.
Ekabolama mingi na moyen orient mpe na Afrika.
It is therefore impossible to sacrifice all camels for the control of MERS, as what was done in wild animal markets in China to prevent the spreading of SARS-CoV and SARS-CoV-2.
Yango wana likoki ezali te ya koboma bakamela nyonso mpo na kobundisa MERS, ndenge esalemaki na bazando ya banyama ya zamba na Chinae mpo na kokanga SARS-CoV mpe SARS-CoV-2 nzela epanzana te.
To stop the recurrent outbreaks of MERS, a comprehensive approach should be taken to develop effective vaccines against MERS-CoV for camels, in combination with other infection control measures.
Mpo na kokanga MERS nzela ebima lisusu te, tosengeli kosala bolukiluki ya malamu mpo na kobimisa mangwele ebongi mpo na MERS-CoV ya bakamela, mpe kotya bipekiseli mosusu mpo na kobundisa maladi wana.
As we are not able to eliminate these viruses, new genotypes might emerge to cause outbreaks.
Lokolo tokoki te kosilisa bavirisi oyo, bagenome ya sika ekoki kobimisa maladi mosusu.
A variety of zoonotic CoVs are circulating in the wild.
Ba CoVs mingi ezali kotambola na kati ya zamba.
Particularly, bat CoVs with zoonotic potential are so diverse.
Mingimingi, CoVs ya banyama oyo ekoki kobima na lolenge mingi mpenza.
There are plenty of opportunities that these zoonotic CoVs evolve and recombine, resulting in the emergence of new CoVs that are more transmissible and/or deadly in humans in future.
Ezali na mabaku mingi mpenza mpo ba CoVs oyo ya banyama ekola mpe esangana lisusu, ebongo ebimisa CoVs ya sika oyo ekopanzana mingi mpe/to ekoboma bato mingi na mikolo ezali koya.
The culture of eating wild animals in some places of China should be abandoned to reduce unnecessary contact between humans and animals.
Ezaleli ya kolya mbisi ya zamba na bisika mosusu ya Chine esengeli kosuka mpo bato bakutana lisusu mingi te na banyama.
With the ordeals of SARS, MERS and COVID-19, a better preparedness and response plan should be in place.
Ndenge SARS, MERS mpe COVID-19 enyokoli biso, tosengeli komibongisa mpe kosala mwango ya kobundisa yango.
In fact, many viruses have existed in the planet for a very long time.
Ya solo, bavirisi mingi bafandi na planete na biso banda kala mpenza.
They stay in their own natural reservoirs until there is a chance for spillover.
Efandaka na bisika na yango kino ezwaka libaku ya kobima.
Although bats have many features that favours the spreading of viruses, the chance for humans to be in contact with bats and other wildlife species can be minimized if people are educated to stay away from them.
Ata ete bangembo bazali na bizaleli mingi oyo esalaka ete bavirisi wana epanzana mingi, tokoki kosala ete bato bakutana lisusu mingi te na bangembo mpe banyama mosusu ya zamba soki toteyi bato na kotikala mosika na banyama wana.
Continuous surveillance in mammals is necessary for better understanding of the ecology of CoVs and their natural hosts, which will prove useful in preventing animal-to-human transmission and future outbreaks.
Kolanda kokengela bamamifere ezali ntina mingi mpo na koyeba ndenge CoVs ezalaka mpe bisika oyo yango efandaka, ebongo ekosalisa na kokanga nzela mpo banyama epesa te bato bavirisi wana mpe ebima lisusu te na mikolo ezali kooya.
To conclude, the most effective way to prevent viral zoonosis is for humans to stay away from the ecological niches of the natural reservoirs of the zoonotic viruses.
Mpo na kosukisa, lolenge eleki malamu ya kokanga nzela na bavirisi oyo eutaka na banyama ezali ete bato bazala mosika na bisika oyo banyama wana ya zamba oyo ezalaka na bavirisi wana efandaka.
Several pieces in the puzzle of the zoonotic origin of SARS-CoV-2 are still missing.
Kino sikoyo toyebi nanu malamu te makambo mosusu etali esika oyo SARS-CoV-2 ya banyama eutaka.
First, if bats transmit an ancestral virus of SARS-CoV-2 to pangolins, it will be of interest to see under what circumstances bats and pangolins could share the same ecological niche.
Ya liboso, soki bangembo epesaki bapangolin virisi ya kala ya SARS-CoV-2, ekozala malamu na koyeba na ndenge nini bangembo na bapangolin bafandaka esika moko.
Second, if bats play a more direct role in human transmission, how humans get into contact with bats should be determined.
Ya mibale, soki bangembo nde bato bapesaki mbala moko virisi wana na bato, esengeli toyeba ndenge nini bato bakutanaki na bangembo.
Third, if a third mammal acts as the true intermediate host, how it interacts with the different species including humans, bats and pangolins has to be clarified.
Ya misato, soki mamifere ya misato nde azali esika ya mibale ya solo oyo virisi efandaka, esengeli kolimbola malamu ndenge nini ekutanaka na bikelamu mosusu ata mpe bato, bangembo mpe bapangolin.
Finally, since many mammals including domestic animals might be susceptible to SARS-CoV-2, both surveillance and experimental infection should be conducted.
Ya nsuka, mpo bamamifere mingi ata mpe banyama ya ndako ekoki kozala na SARS-CoV-2, esengeli mpe koluka kokengela yango mpe koluka koyeba soki ezalaka na maladi wana.
Should it be a bat, a pangolin or another mammal, it is expected that SARS-CoV-2 or its parental viruses that are almost identical will be identified in its natural hosts in future.
Ezali nde ngembo, pangolin to mamifere mosusu, esegami ete tozela SARS-CoV-2 to bavirisi mosusu oyo ebimisaka yango oyo ekokani mpenza na yango, ekoyebana na bisika oyo efandaka na mikolo ezali koya.
Continued investigations in this area will elucidate the evolutionary pathway of SARS-CoV-2 in animals, with important implications in the prevention and control of COVID-19 in humans.
Kokoba kolandela makambo wana ekoki kosalisa na koyeba ndenge SARS-CoV-2 ekolaka na banyama, mpe yango eza na bopusi mingi na kobundisa mpe kobatela bato na COVID-19.
Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020
Makanisi ya ebandeli etali kobima ya bikolo baponi oyo ezomonisa sante ya bato oyo bazwi maladi coronavirisi 2019 — Etats-Unis, mokolo ya 12 sanza ya mibale– mokolo ya 28 sanza ya misato 2020
On March 11, 2020, the World Health Organization declared Coronavirus Disease 2019 (COVID-19) a pandemic.
Na mokolo ya 11 sanza ya misato 2020, organisation mondiale de la santé elobaki eza coronavirisi 2019 (COVID-19) eza maladi mabe.
As of March 28, 2020, a total of 571,678 confirmed COVID-19 cases and 26,494 deaths have been reported worldwide.
Na mokolo ya 28 sanza ya misato 2020, bato 571 678 bazwaki maladi ya COVID-19 mpe bato 26 494 bakufaki na yango na mokili mobimba.
Reports from China and Italy suggest that risk factors for severe disease include older age and the presence of at least one of several underlying health conditions.
Bansango euti na Chine mpe na Italie makambo oyo ezosala bato babela makasi eza kimobange mpe kozala deja ata na maladi moko ya makasi.
U.S. older adults, including those aged ≥65 years and particularly those aged ≥85 years, also appear to be at higher risk for severe COVID-19–associated outcomes; however, data describing underlying health conditions among U.S. COVID-19 patients have not yet been reported.
Mibange mosusu ya Etats-Unis, ata mpe baoyo baza na mibu ≥65 mpe mingimingi baoyo baza na bambula ≥85, emonani ete baza na likambo mingi ya kobela makasi maladi euti na COVID-19; kasi, bansango oyo ezomonisa sante na kati ya bato ya Etats-Unis oyo bazobela COVID-19 eyebisami nanu te.
As of March 28, 2020, U.S. states and territories have reported 122,653 U.S. COVID-19 cases to CDC, including 7,162 (5.8%) for whom data on underlying health conditions and other known risk factors for severe outcomes from respiratory infections were reported.
Na mokolo ya 28 sanza ya misato 2020, Etats-Unis na bateritware na yango ezalaki na bato 122 653 oyo bazalaki kobela. CoVID-19 to CDC, tango mpe bato 7 162 (5,8%) oyo bansango ya santé na bango mpe makama mosusu eyebani oyo esalaki ete bazala na mpasi makasi ya kopema elobelamaki.
Among these 7,162 cases, 2,692 (37.6%) patients had one or more underlying health condition or risk factor, and 4,470 (62.4%) had none of these conditions reported.
Na kati ya bato 7 162 wana bato 2 692 (37,.6%) bazalaki na moko to mingi ya maladi wana to likama moko, mpe bato 4 470 (62,4%) bazalaka ata na moko te ya makambo wana.
The percentage of COVID-19 patients with at least one underlying health condition or risk factor was higher among those requiring intensive care unit (ICU) admission (358 of 457, 78%) and those requiring hospitalization without ICU admission (732 of 1,037, 71%) than that among those who were not hospitalized (1,388 of 5,143, 27%).
Pourcentage ya bato ya COVID-19 oyo baza ata na maladi moko to likama moko ezalaki mingi na kati ya bato oyo esengaki ete bakota na soins intensifs (ICU) (358 na kati ya 457, 78%) mpe bato esengaki bakota lopitalo kozanga kokota na ICU (732 na kati ya 1 037, 71%) koleka baoyo bakotaki te na lopitalo (1 388 na kati ya 5 143, 27%).
The most commonly reported conditions were diabetes mellitus, chronic lung disease, and cardiovascular disease.
Maladi oyo bato mingi bazalaki na yango ezalaki diabete, maladi ya poumon oyo esilaka te mpe maladi ya motema.
These preliminary findings suggest that in the United States, persons with underlying health conditions or other recognized risk factors for severe outcomes from respiratory infections appear to be at a higher risk for severe disease from COVID-19 than are persons without these conditions.
Bokundoli oyo ya ebandeli emonisi ete na Etats-Unis, bato oyo baza na maladi mosusu to makambo mossu ya makama mpo na maladi makasi ya mpema baza na likama mingi mpo na kozwa kobela makasi maladi ya COVID-19 koleka bato oyo baza na maladi wana te.
Data from laboratory-confirmed COVID-19 cases reported to CDC from 50 states, four U.S. territories and affiliated islands, the District of Columbia, and New York City with February 12–March 28, 2020 onset dates were analyzed.
Bansango ya laboratoire ya bato oyo baza na COVID-19 oyo bayebisaki CDC euti na bituka 50, batertiware minei ya Etats-Unis mpe bisanga na yango, Etuka ya Columbia, mpe engumba New York City na mokolo ya 12 sanza ya mibale–mokolo ya 28 sanza ya misato 2020, batalelaki badate oyo ebandaki.
Cases among persons repatriated to the United States from Wuhan, China, and the Diamond Princess cruise ship were excluded.
Batangaki te bato ya maladi ya Etats-Unis oyo bautaki na Wuhan, na Chine, mpe na maswa Diamond Princess.
For cases with missing onset dates, date of onset was estimated by subtracting 4 days (median interval from symptom onset to specimen collection date among cases with known dates in these data) from the earliest specimen collection.
Mpo na bato oyo bayebi te date oyo ebandaki, batyaki date ya ebandeli kaka bongo na kolongolaka mikolo 4 (na kotalela mokolo oyo bilembo ebandaka na bandakisa ya bansango oyo bazwaki na bato oyo baza deja na maladi yango) banda na ndakisa ya liboso mpenza oyo bazwaki.
Public health departments reported cases to CDC using a standardized case report form that captures information (yes, no, or unknown) on the following conditions and potential risk factors: chronic lung disease (inclusive of asthma, chronic obstructive pulmonary disease [COPD], and emphysema); diabetes mellitus; cardiovascular disease; chronic renal disease; chronic liver disease; immunocompromised condition; neurologic disorder, neurodevelopmental, or intellectual disability; pregnancy; current smoking status; former smoking status; or other chronic disease.
Ministere ya santé eyebisaka CDC motango ya bato bazobela na kosalelaka lolenge moko eyebani ya kopesa rapore oyo elobelaka bansango (ee, te, to eyebani te) na maladi elandi mpe makama mosusu: maladi ya poumon oyo esilaka te (ata mpe asthme, maladi ya poumon ya makasi oyo esilaka te [COPD], mpe emphysème); diabete; maladi ya motema; maladi ya bangeyi oyo esilaka te; maladi ay foie oyo esilaka te; mikrobe oyo ebundisaka maladi esi elemba; maladi ya moto, maladi ya boongo, to maladi ya kokoka te kokanga makambo; zemi; bato oyo bamelaka makaya mingi; bato oyo bazalaki komela makaya kala; mpe maladi mosusu oyo esilaka te.
Data reported to CDC are preliminary and can be updated by health departments over time; critical data elements might be missing at the time of initial report; thus, this analysis is descriptive, and no statistical comparisons could be made.
Bansango oyo bapesaki CDC eza ya ebandeli mpe bakoki kobongola yango na ministere ya santé na nsima; bansango ya ntina ekoki kozanga ntango tozosala rapore oyo ya ebandeli; yango wana, bolukiluki oyo ezolimbola kaka, mpe toza te na likoki ya kokokanisa bansango.
The percentages of patients of all ages with underlying health conditions who were not hospitalized, hospitalized without ICU admission, and hospitalized with ICU admission were calculated.
Pourcentange ya bato ya maladi ya bambula nyonso oyo ezomonisa kolongono ya nzoto mpe oyo bakotaki te lopitalo, oyo bakotaki lopitalo kasi na ICU te, mpe oyo bakotaki lopitalo mpe bakotaki na ICU etangamaki.
Percentages of hospitalizations with and without ICU admission were estimated for persons aged ≥19 years with and without underlying health conditions.
Pourcentage ya bato bakotaki lopitalo oyo bakotaki na ICU mpe oyo bakotaki te na esika wana, batalelaki yango mpo na bato ya mibu ≥19 ezala bazalaki na maladi mosusu to bazalaka na yango te.
This part of the analysis was limited to persons aged ≥19 years because of the small sample size of cases in children with reported underlying health conditions (N = 32).
Eteni oyo ya botaleli esukaki na bato oyo baza na mibu ≥19 mpo tozalaki kaka na bandakisa mike ya bana oyo bazalaka na maladi mosusu (N = 32).
To account for missing data among these preliminary reports, ranges were estimated with a lower bound including cases with both known and unknown status for hospitalization with and without ICU admission as the denominator and an upper bound using only cases with known outcome status as the denominator.
Mpo na kotalela bansango oyo ezangi na rapore oyo ya ebandeli, totalelaki yango na nivo ya nse na kotalela bato oyo eyebani mpe oyo eyebani te ete bakotaki lopitalo mpe bakotaka na ICU to te, yango nde eloko tosalelaki lokola eloko ya ntina mpe elembo ya likolo mpe tosalelaki kaka bato oyo sort na bango eyebani.
Because of small sample size and missing data on underlying health conditions among COVID-19 patients who died, case-fatality rates for persons with and without underlying conditions were not estimated.
Mpo tozalaki na bandakisa moke mpe tozalaki te na bansango ya maladi ya kala na kati ya bato oyo babelaki COVID-19 oyo bakufaki, tokokaki te kolobela taux ya liwa ya bato oyo bazalaki na maladi ya kala mpe baoyo bazalaki na yango te.
As of March 28, 2020, a total of 122,653 laboratory-confirmed COVID-19 cases (Figure) and 2,112 deaths were reported to CDC.
Na mokolo ya 28 sanza ya misato 2020, bayebisaki CDC ete bato 122 653 bazalaki na maladi ya COVID-19 (Motango) mpe bato 2 112 bakufaki.
Case report forms were submitted to CDC for 74,439 (60.7%) cases.
Batindaki formilere ya rapore na CDC mpo na bato 74 439 (60,7%).
Data on presence or absence of underlying health conditions and other recognized risk factors for severe outcomes from respiratory infections (i.e., smoking and pregnancy) were available for 7,162 (5.8%) patients (Table 1).
Bansango etali kozala to kozanga ya maladi mpe makama mosusu ya makasi oyo euti na maladi ya mpema (na ndakisa, komela makaya mpe zemi) ezalaki mpo na bato 7 162 (5,8%) (Tablo 1).
Approximately one third of these patients (2,692, 37.6%), had at least one underlying condition or risk factor.
Emonani ete moto moko na kati ya bato misato ya bato ya maladi (2 692, 37,6%), azalaka ata na mwa maladi moko to likama moko.
Diabetes mellitus (784, 10.9%), chronic lung disease (656, 9.2%), and cardiovascular disease (647, 9.0%) were the most frequently reported conditions among all cases.
Diabete (784, 10,9%), maladi ya poumon oyo esilaka te (656, 9,2%), mpe maladi ya motema (647, 9,0%) ezalaki maladi oyo bato mingi bazalaki na yango.
Among 457 ICU admissions and 1,037 non-ICU hospitalizations, 358 (78%) and 732 (71%), respectively occurred among persons with one or more reported underlying health condition.
Na kati ya bato 457 oyo bakotaki na ICU mpe bato 1 037 oyo bakotaki lopitalo kasi bakotaki te na ICU, 358 (78%) mpe 732 (71%), ezalaki na kati ya bato oyo bazalaka na maladi moko to mingi.
In contrast, 1,388 of 5,143 (27%) COVID-19 patients who were not hospitalized were reported to have at least one underlying health condition.
Na kokesena, bato 1 388 na kati ya 5 143 (27%) ya COVID-19 oyo bakotaki te lopitalo, rapore emonisaki ete bazalaki ata na moko ya bamaladi oyo tolobeli.
Among patients aged ≥19 years, the percentage of non-ICU hospitalizations was higher among those with underlying health conditions (27.3%–29.8%) than among those without underlying health conditions (7.2%–7.8%); the percentage of cases that resulted in an ICU admission was also higher for those with underlying health conditions (13.3%–14.5%) than those without these conditions (2.2%–2.4%) (Table 2).
Na kati ya bato ya maladi oyo bazalaki na mibu ≥19, pourcentage ya bato oyo bakotaki lopitalo kasi bakotaki te na ICU eza mingi na bato oyo bazalaka deja na maladi ya kala (27,3%–29,8%) koleka bato oyo bazalaki te na maladi ya kala (7.2%–7,8%); pourcentage ya bato oyo bakotaki na ICU ezalaki mingi koleka ya bato oyo bazalaki na maladi ya kala (13,3%–14,5%) koleka bato oyo bazalaki te na maladi ya kala (2,2%–2,4%) (Tablo 2).
Small numbers of COVID-19 patients aged &lt; 19 years were reported to be hospitalized (48) or admitted to an ICU (eight).
Motango ya moke ya bato ya COVID-19 oyo bazalaki na mibu &lt; 19 bakotaki na lopitalo (48) to bakotaki na ICU (mwambe).
In contrast, 335 patients aged &lt; 19 years were not hospitalized and 1,342 had missing data on hospitalization.
Na bokeseni, bato 335 oyo bazalaki na mobu &lt; 19 oyo bakotaki te na lopitalo mpe 1 342 bazalaki na bansango emonisi bakotisa lopitalo.
Among all COVID-19 patients with complete information on underlying conditions or risk factors, 184 deaths occurred (all among patients aged ≥19 years); 173 deaths (94%) were reported among patients with at least one underlying condition.
Na kati ya bato nyonso ya COVID-19 oyo baza na bansango nyonso ya maladi ya kala to makama, bato 184 bakufaki (na kati ya bato oyo bazalaki na mobu ≥19); bato 173 bakufaki (94%), balobaki yango te na bato ya maladi oyo bazalaki deja ata na maladi moko.
Among 122,653 U.S. COVID-19 cases reported to CDC as of March 28, 2020, 7,162 (5.8%) patients had data available pertaining to underlying health conditions or potential risk factors; among these patients, higher percentages of patients with underlying conditions were admitted to the hospital and to an ICU than patients without reported underlying conditions.
Na kati ya bato ya Etats-Unis 122 653 oyo bazobela COVID-19 oyo bayebisaki CDC na mokolo ya 28 sanza ya misato 2020, bato ya maladi 7 162 (5,8%) baza na bansango emonisi bazalaki kobela kala to na makama mosusu; na kati ya bato wana ya maladi, pourcentage ya mingi ya bato ya maladi oyo bazalaki na maladi ya kala bakotaki na lopitalo mpe bakotaki na ICU koleka bato oyo bazalaki te deja na maladi ya kala.
These results are consistent with findings from China and Italy, which suggest that patients with underlying health conditions and risk factors, including, but not limited to, diabetes mellitus, hypertension, COPD, coronary artery disease, cerebrovascular disease, chronic renal disease, and smoking, might be at higher risk for severe disease or death from COVID-19.
Ba résultat eyokani na bolukiluki euti na Chine mpe Italie, emonisi ete bato oyo bazalaki na maladi ya kala mpe makama, ata mpe, kasi esuki te, diabete, hypertension, COPD, maladi ya ba artere, maladi ya boongo, maladi ya bangeyi oyo esilaka te, mpe komela makaya, bakoki kozala na risque makasi ya kobela makasi to ya kokufa soki babeli COVID-19.
This analysis was limited by small numbers and missing data because of the burden placed on reporting health departments with rapidly rising case counts, and these findings might change as additional data become available.
Botaleli oyo esukaki na motango moke mpe bansango mosusu ezangi mpo na kilo oyo batye likolo ya minganga mpo bapesa rapore na ministere ya santé na ndenge ntalo ya bato ya maladi ezomata noki, mpe makambo oyo ekoki kobongwana soki tozwi bansango ya sika.
It is not yet known whether the severity or level of control of underlying health conditions affects the risk for severe disease associated with COVID-19.
Eyebani nanu te soki makasi to nivo ya maladi ya kala ekoki kosala ete bato babela maladi makasi oyo euti na COVID-19.
Many of these underlying health conditions are common in the United States: based on self-reported 2018 data, the prevalence of diagnosed diabetes among U.S. adults was 10.1%, and the U.S. age-adjusted prevalence of all types of heart disease (excluding hypertension without other heart disease) was 10.6% in 2017.
Mingi ya maladi oyo ezalaka mingi na Etats-Unis: na kolanda bansango oyo bato bango moko bapesaki na 2018, mibange ya Etats-Unis oyo bazobela diabete ezalaki 10,1%, mpe bato ya Etats-Unis oyo bazobela maladi nyonso ya motema (tolongoli hypertension oyo ezangi maladi mosusu ya motema) ezalaki 10,6% na 2017.
The age-adjusted prevalence of COPD among U.S. adults is 5.9%, and in 2018, the U.S. estimated prevalence of current asthma among persons of all ages was 7.9%.
Pourcentage ya bato babelaka COPD na kati ya mikolo ya Etats-Unis eza 5,9%, mpe na 2018, Etats-Unis emonaki ete bato ya bambula nyonso oyo bazalaki kobela asthme ezalaki 7,9%.
CDC continues to develop and update resources for persons with underlying health conditions to reduce the risk of acquiring COVID-19.
CDC ekozoba kobongisa mpe kotya bansango ya sika ya bato oyo bazalaki na maladi ya kala mpo na kokitisa likama ya kozwa COVID-19.
The estimated higher prevalence of these conditions among those in this early group of U.S. COVID-19 patients and the potentially higher risk for more severe disease from COVID-19 associated with the presence of underlying conditions highlight the importance of COVID-19 prevention in persons with underlying conditions.
Komata ya mingi ya maladi oyo na kati ya bato ya Etats-Unis oyo baza na COVID-19 mpe likama monene ya kozwa maladi makasi euti na COVID-19 mpo baza na maladi deja na maladi ya kala ezomonisa ntina ya kobatela bato oyo baza deja na COVID-19.
The findings in this report are subject to at least six limitations.
Makambo oyo eza na rapore oyo eza na bandelo pene ya motoba.
First, these data are preliminary, and the analysis was limited by missing data related to the health department reporting burden associated with rapidly rising case counts and delays in completion of information requiring medical chart review; these findings might change as additional data become available.
Ya liboso, bansango oyo eza ya ebandeli, mpe botaleli ezalaki ya mobimba te mpo ministere ya santé ezoloba ete basengeli kotya bansango ya sika mbala na mbala na ndenge bantalo ezomata noki mpenza mpe eza mpasi na kozwa bansango ya nsuka oyo ezosenga minganga batalela; makambo oyo ekoki kobongwana soki tozwi bansango ya sika.
Information on underlying conditions was only available for 7,162 (5.8%) of 122,653 cases reported to CDC.
Bansango etali maladi ya kala ezalaki kaka mpo na bato 7 162 (5,8%) na kati ya bato 122 653 oyo bapesaki rapore na bango na CDC.
It cannot be assumed that those with missing information are similar to those with data on either hospitalizations or underlying health conditions.
Tokoki koloba te ete bato oyo bansango na bango ezangi baza ndenge moko na bato oyo bansango na bango na oyo etali kokota lopitalo to soki bazalaki deja na maladi.
Second, these data are subject to bias in outcome ascertainment because of short follow-up time.
Ya mibale, tokoki kotyela ba résultat oyo ntembe mpo toza na ntango mingi te mpo na kotalela yango.
Some outcomes might be underestimated, and long-term outcomes cannot be assessed in this analysis.
Ba résulat ekoki kozala moke, mpe tokoki te kolobela résulat ya nsuka na lisolo oyo.
Third, because of the limited availability of testing in many jurisdictions during this period, this analysis is likely biased toward more severe cases, and findings might change as testing becomes more widespread.
Ya misato, mpo toza te na ba résultat ya ba ekzame ya bisika mingi na eleko oyo, botaleli oyo ekozala na makambo mosusu ya solo mpenza te mpo makambo ya makasi, mpe tokoki kobongola yango soki ba résulat ya ba ekzame mosusu ebimi polele.
Fourth, because of the descriptive nature of these data, attack rates among persons with and without underlying health conditions could not be compared, and thus the risk difference of severe disease with COVID-19 between these groups could not be estimated.
Ya minei, mpo na ndenge tolimboli bansango oyo, tokokaki te kokokanisa pourcentage ya maladi na kati ya bato oyo bazalaki deja na maladi to te, yango wana tokoki kolobela te bokeseni oyo eza na kati ya COVID-19 na kati ya bituluku wana.
Fifth, no conclusions could be drawn about underlying conditions that were not included in the case report form or about different conditions that were reported in a single, umbrella category.
Ya mitano, tokoki kozwa bosukisi moko te mpo na maladi oyo bakotisaki te na formilere ya rapore oyo to mpo na maladi ya ndenge na ndenge oyo balobelaki kaka na moto moko mpamba.
For example, asthma and COPD were included in a chronic lung disease category.
Na ndakisa, bakotisaki te asthme na COPD na kati ya maladi ya poumon oyo esilaka te.
Finally, for some underlying health conditions and risk factors, including neurologic disorders, chronic liver disease, being a current smoker, and pregnancy, few severe outcomes were reported; therefore, conclusions cannot be drawn about the risk for severe COVID-19 among persons in these groups.
Ya nsuka, mpo na maladi ya kala mpe makama, ata mpe maladi ya moto, maladi ya foie oyo esilaka te, kozala momeli makaya mpe zemi, balobelaki bato moke oyo babelaki makasi; yango wana, tokoki koloba eloko te mpo na likama ya kobela makasi COVID-19 na kati ya bato ya bituluku wana.
Persons in the United States with underlying health conditions appear to be at higher risk for more severe COVID-19, consistent with findings from other countries.
Emonani ete bato ya États-Unis oyo bazalaki deja na maladi wana baza na likama mingi ya kobela makasi na COVID-19, na kotalela makambo emonani na mikili mosusu.
Persons with underlying health conditions who have symptoms of COVID-19, including fever, cough, or shortness of breath, should immediately contact their health care provider.
Bato oyo bazalaki deja na maladi wana oyo bazalaki na bilembo ya COVID-19, ata mpe fievre, kosukosu, to mpema ezokatana, basengeli kobeta monganga na lombango.
These persons should take steps to protect themselves from COVID-19, through washing their hands; cleaning and disinfecting high-touch surfaces; and social distancing, including staying at home, avoiding crowds, gatherings, and travel, and avoiding contact with persons who are ill.
Bato oyo basengeli komibatela na COVID-19, yango wana basengeli kosokolaka maboko; kotya bopeto mpe ko desinfecter bisika oyo bato basimbaka mingi; kozala mosika na bato mosusu, ata mpe kotikala na ndako, koboya kozala esika ya bato mingi, na makita, mpe kosala mobembo, mpe koboya kokutana na bato oyo bazobela.
Maintaining at least a 30-day supply of medication, a 2-week supply of food and other necessities, and knowledge of COVID-19 symptoms are recommended for those with underlying health conditions.
Kozala na nkisi ata mpo na mikolo 30, bilei ya mposo 2 mpe kozala na biloko mosusu ya ntina, mpe koyeba bilembo ya COVID-19 eza ntina mingi mpo na bato oyo baza deja na maladi wana.
All persons should take steps to protect themselves from COVID-19 and to protect others.
Bato nyonso basengeli komibatela na COVID-19 mpe kobatela bato mosusu.
All persons who are ill should stay home, except to get medical care; should not go to work; and should stay away from others.
Bato nyonso oyo bazobela basengeli kotikala na ndako, longola kaka mpo na kokende kokutana na monganga; basengeli kokende na mosala te; mpe basengeli kozala mosika na bato mosusu.
This is especially important for those who work with persons with underlying conditions or who otherwise are at high risk for severe outcomes from COVID-19.
Kosala bongo eza ntina mingi mpo na bato oyo basalaka na bato oyo babelaka deja maladi wana to mpo na bantina mosusu baza na likambo ya kobela makasi maladi ya COVID-19.
Community mitigation strategies, which aim to slow the spread of COVID-19, are important to protect all persons from COVID-19, especially persons with underlying health conditions and other persons at risk for severe COVID-19–associated disease (https://www.cdc.gov/coronavirus/2019-ncov/downloads/community-mitigation-strategy.pdf).
Mayele ya kobatela bato ya mboka, oyo mokano na yango eza ya kolembisa kopanzana ya COVID-19, eza ntina mingi mpo na kobatela bato nyonso na COVID-19, mingimingi bato oyo baza deja na maladi wana mpe bato mosusu oyo baza na likambo ya kobela makasi maladi euti na COVID-19(https://www.cdc.gov/coronavirus/2019-ncov/downloads/community-mitigation-strategy.pdf).
What is already known about this topic?
Nini tosi toyebi mpo na likambo oyo?
Published reports from China and Italy suggest that risk factors for severe COVID-19 disease include underlying health conditions, but data describing underlying health conditions among U.S. COVID-19 patients have not yet been reported.
Barapore babimisi oyo euti na Chine mpe na Italie emonisi ete makambo ya minene oyo ekoki kosala ete moto abela makasi maladi ya COVID-19 eza na ndakisa soki azalaki deja kobela kala, kasi bansango oyo ezolimbola maladi wana na kati ya bato ya États-Unis bazobela COVID-19 eyebisami nanu te.
What is added by this report?
Nini ebakisami na rapore oyo?
Based on preliminary U.S. data, persons with underlying health conditions such as diabetes mellitus, chronic lung disease, and cardiovascular disease, appear to be at higher risk for severe COVID-19–associated disease than persons without these conditions.
Na kotalela bansango ya ebandeli ya États-Unis, emonani ete bato oyo baza deja na maladi ya kala na ndakisa diabete, maladi ya poumon oyo esilaka te, mpe maladi ya motema, baza na likama mingi ya kobela makasi maladi euti na COVID-19 koleka bato oyo baza te na maladi wana.
What are the implications for public health practice?
Mosala ya bato oyo basalisaka bato ekozala nini?
Strategies to protect all persons and especially those with underlying health conditions, including social distancing and handwashing, should be implemented by all communities and all persons to help slow the spread of COVID-19.
Mayele mpo na kobatela bato nyonso mpe mingimingi bato yo baza deja na maladi ya kala, na ndakisa kozala mosika na bato mpe kosokola maboko, esengeli kosalelama bisika nyonso mpe na bato nyonso mpo COVID-19 epanzana mingi te.
Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England
Kobima ya coronavirisi ya sika (COVID-19): Malako mpo kolandela bokengi oyo esalelamaki na Minganga ya College Royal, centre ya bolukiluki mpe ya kokengela mpe kolongono ya nzoto ya bato nyonso ya Angleterre
The Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) and Public Health England (PHE) have successfully worked together on the surveillance of influenza and other infectious diseases for over 50 years, including three previous pandemics.
Minganga ya College Royal (RCGP) mpe centre ya bolukiluki mpe ya kokengela (RSC) mpe kolongono ya nzoto ya bato nyonso ya Angleterre (PHE), basalaki elongo mpo na kokengela grippe mpe maladi mosusu na eleko ya mibu koleka 50, ata mpe maladi mabe misato oyo esi eleka .
With the emergence of the international outbreak of the coronavirus infection (COVID-19), a UK national approach to containment has been established to test people suspected of exposure to COVID-19.
Ndenge maladi ya sika ya coronovirisi (COVID-19) oyo epanza na mokili mobimba, mayele oyo bato ya Royaume-Uni basalelaki mpo na kokanga maladi nzela ebimisami mpo na kosala ekzame na bato nyonso oyo mbala mosusu bakutanaki na bato ya COVID-19.
At the same time and separately, the RCGP RSC’s surveillance has been extended to monitor the temporal and geographical distribution of COVID-19 infection in the community as well as assess the effectiveness of the containment strategy.
Na ntango wana moko mpe na kokabwana, bokengi ya RCGP RSC ekoma mingi mpe ekoma kolandela ndenge maladi ya COVID-19 ezopanzana na bamboka mpe kotalela soki mayele ya komibatela ezosimba.
The aims of this study are to surveil COVID-19 in both asymptomatic populations and ambulatory cases with respiratory infections, ascertain both the rate and pattern of COVID-19 spread, and assess the effectiveness of the containment policy.
Mokano ya bolukiluki oyo eza ya kokengela COVID-19 na bato oyo baza na bilembo na yango mpe na bato oyo baza na maladi ya mpema, kotalela taux ya kopanzana ya COVID-19 mpe ndenge ezali, mpe kotalela bokasi ya mayele ya komibatela.
The RCGP RSC, a network of over 500 general practices in England, extract pseudonymized data weekly.
RCGP RSC, lisanga ya minganga koleka 500 ya Angleterre, babimisaka bansango mposo nyonso.
This extended surveillance comprises of five components: (1) Recording in medical records of anyone suspected to have or who has been exposed to COVID-19.
Bokengi oyo ezotalela makambo mitano: (1) Lisolo ya makambo ya monganga ya moto nyonso bakanisi akutanaki na bato ya COVID-19 to oyo akutanaki mpenza na bango.
Computerized medical records suppliers have within a week of request created new codes to support this.
Nsima ya mposo bato basengi lisalisi mpo babanda kokotisa bansango ya makambo ya kolongono ya nzoto na ordinatere.
(2) Extension of current virological surveillance and testing people with influenza-like illness or lower respiratory tract infections (LRTI)—with the caveat that people suspected to have or who have been exposed to COVID-19 should be referred to the national containment pathway and not seen in primary care.
(2) Kokoba kokengela maladi ya virisi mpe kosalisa bato baekzame ndenge basalaka mpo na grippe to maladi mosusu ya mpema ya makasi te (LRTI)—na bato oyo bakanisi ete baza na COVID-19 to oyo mbala mosusu bakutanaki na moto aza na yango, esengeli kolanda mayele ya kobatela bato mpe komema bango te na premiers soins.
(3) Serology sample collection across all age groups.
(3) Serologie ya bato ya bambula nyonso.
This will be an extra blood sample taken from people who are attending their general practice for a scheduled blood test.
Ekozala makila mosusu oyo bazwi na ya bato oyo bazokende na lopitalo mpo na baekzame na bango ya makila.
The 100 general practices currently undertaking annual influenza virology surveillance will be involved in the extended virological and serological surveillance.
Minganga 100 oyo bakengelaka sikoyo maladi eutaka na virisi ndakisa grippe mbula nyonso bakosalisa mpe na botali ya virisi oyo mpe kokengele serologie na yango.
(4) Collecting convalescent serum samples.
(4) Kozwa serum oyo bato oyo baza na kobika.
We have the opportunity to escalate the data extraction to twice weekly if needed.
Toza na libaku ya komatisa motango ya bansango tozozwa mbala mibale na mposo soki toza na mposa na yango.
Swabs and sera will be analyzed in PHE reference laboratories.
Bakotalela biloko bazwi mpe sera na balaboratoire ya PHE.
General practice clinical system providers have introduced an emergency new set of clinical codes to support COVID-19 surveillance.
Bato oyo bapesaka lolenge ya kosala makambo na minganga bakotisa mayele ya sika ya bakode mpo na kosalisa na kokengela COVID-19.
Additionally, practices participating in current virology surveillance are now taking samples for COVID-19 surveillance from low-risk patients presenting with LRTIs.
Lisusu, minganga oyo bazosangana na bokengeli ya virisi bazozwa makila ya bato ya COVID-19 sikoyo na bato oyo baza na likama makasi te oyo baza na bilembo ya LRTIs.
Within the first 2 weeks of setup of this surveillance, we have identified 3 cases: 1 through the new coding system, the other 2 through the extended virology sampling.
Nsima ya mposo 2 ya kobandisa bokengeli oyo, tokangi bato 3: 1 na nzela ya lolenge ya sika ya kode, 2 mosusu na nzela ya botaleli molai ya virisi.
We have rapidly converted the established national RCGP RSC influenza surveillance system into one that can test the effectiveness of the COVID-19 containment policy.
Tobongoli na lombango systeme ya kokengela bato ya nyonso oyo RCGP RSC esalaka mpo na grippe mpo ekoma kosalisa na komeka bokesa ya mayele tozosalela mpo na komibatela na COVID-19.
The extended surveillance has already seen the use of new codes with 3 cases reported.
Na bokengeli ya molai basi basaleli bakode ya sika, mpe bakangi bato 3.
Rapid sharing of this protocol should enable scientific critique and shared learning.
Kokabola noki mayele wana ekosalisa bato ya siansi mpe ekosalisa na kokabola mayele.
The Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) is a network of general practices (GPs) with a nationally representative population that provides pseudonymized data for weekly surveillance of infectious diseases.
College Royal ya minganga (RCGP) centre ya bolukiluki mpe ya kokengela (RSC) eza lisanga ya minganga (GPs) ya bamboka mingi oyo ezosalisa na kozwa mposo nyonso bansango ya maladi.
The disease surveillance program is commissioned by Public Health England (PHE) and covers 37 infectious diseases, including influenza.
Programe ya kokengela maladi ekambami na kolongono ya nzoto ya bato nyonso ya Angleterre (PHE) mpe elandelaka maladi 37 ata mpe grippe.
The RCGP RSC and PHE have an established collaboration of over 50 years in influenza and respiratory disease surveillance and are now in their 53rd season of surveillance and analysis.
RCGP RSC mpe PHE esala elongo banda bambula koleka 50 na kokengela grippe mpe maladi ya mpema mpe sikoyo baza na mobu ya 53 ya kokongela mpe kotalela.
The RCGP RSC extracts pseudonymized data from a nationally representative sample of over 500 urban and nonurban GPs each week covering a population of over 4 million.
Bansango oyo RCGP RSC ezwaka na bato ya bingumba koleka 500 mpe bamboka-mike GP mposo nyonso ezalaka mpo na bato pene ya bamilio 4.
Data from these practices are reported online in a weekly return, which includes monitoring weekly rates of influenza-like illness (ILI) and other communicable and respiratory diseases in England.
Bansango euti na minganga oyo, batyaka yango na internet mposo nyonso, yango etalaka kolandela taux ya maladi euti na grippe (ILI) mpe maladi mosusu oyo epanzanaka mpe maladi mosusu ya mpema na Angleterre.
We also produce an annual report.
Tosalaka mpe rapore ya nsuka-mbula.
The RCGP RSC data set includes all coded data and all prescribed items including vaccine exposure.
Bansango ya RCGP RSC ezalaka na bansango nyonso eza na bakode mpe makambo mosusu ndakisa mangwele.
The RCGP RSC conducts virology surveillance each influenza season, with 100 GPs participating in the 2019-2020 season (Figure 1).
Ndenge RCGP RSC ekengelaka virisi ya grippe na eleko nyonso, mpe 100 GPs basanganaki na eleko ya 2019-2020 (Motango 1).
These virology sampling practices are also recruited to be nationally representative (Figure 1).
Bandakisa oyo ya bavirisi ezalaka mpe mpo na mokili moko ya mobimba (Figure 1).
GPs take nasopharyngeal swabs from persons showing acute respiratory illness within 7 days of the onset of symptoms.
GPs bilembo biloko eza na zolo ya bato oyo bazalaka na maladi makasi ya mpema na nsima ya mikolo 7 banda bilembo na yango ebandi komanana.
Nasopharyngeal swabs are taken from children younger than 5 years showing symptoms of acute bronchitis or bronchiolitis.
Bilembo ya biloko ya zolo ezwamaka na bana bakokisi nanu te mibu 5 oyo baza na bilembo ya bronchite to bronchiolite ya makasi.
Additionally, nasopharyngeal samples are taken from anyone 5 years and older showing acute onset of ILI and respiratory synctial virus.
Lisusu, bilembo ya biloko ya zolo ezwamaka na bana ya mibu 5 mpe mata oyo baza na ebandeli ya maladi makasi ya ILI mpe virisi ya maladi ya mpema.
Swabs are tested at the PHE Respiratory Virus Unit for influenza to monitor positivity rates and circulating strains, as well as for measuring vaccine effectiveness.
Basalaka bilembo wana ekzame na PHE Esika basalaka ekzame ya virisi ya mpema mpo na grippe mpo na kotala taux na yango mpe bokoli na yango, mpe kotala soki mangwele ezosimba.
The RCGP RSC successfully conducted a pilot collecting serological samples from adults and linking them to a patient’s medical records during the 2018-2019 influenza season.
RCGP RSC esi ebongisa ndenge ya kozwa bansango ya mikolo mpe koyokanisa yango na lisolo ya maladi ya moto yango na eleko ya grippe ya 2018-2019.
This pilot was in collaboration with the PHE Seroepidemiology Unit and added to the residual blood samples submitted to PHE by National Health Service (NHS) laboratories.
Mayele oyo esalelamki na boyokani na PHE eteni ya seroepidemioloie mpe babakisaki makila eutaka na ndako ya bato oyo batindaki yango na balaboratoire ya ministere ya sante publique (NHS).
Serology can provide important information about background population immunity, and sentinel networks can provide a mechanism for systematic data collection and linkage to medical records and health outcomes.
Serologie ekoki kopesa bansango ya ntina etali makasi ya bato ya kobundisa maladi, mpe reseaux mosusu ekoki kosalisa na kozwa bansango mpe kokokanisa yango na lisolo ya sante mpe kolongono ya nzoto.
The serology pilot has demonstrated the ability of the network to collect serology samples in adults.
Mayele ya serologie emonisa ete reseaux yango eza na makoki ya kozwa bansango ya mikolo.
With the COVID-19 outbreak, PHE and RCGP RSC have adapted existing influenza surveillance to monitor the spread of COVID-19 in the community, and this protocol sets out the basis for that collaboration.
Na kobima ya COVID-19, PHE na RCGP RSC babongoli mayele na bango ya kokengela grippe mpo na kolandela bokoli ya COVID-19 na mboka mpe malako oyo ekosalisa mpo na boyokani wana.
The primary national strategy for COVID-19 infection is containment, with patients who are at high risk managed via the telephone help system NHS111 and the PHE health protection teams, but the RCGP RSC surveillance is entirely separate.
Mayele ya liboso mpo na maladi ya COVID-19 eza kokanga yango nzela mpo epanzana te; bato ya maladi oyo baza likama ekosenga kosalisa na bango na telefone NHS111 mpe ba-ekipe ya PHE oyo ebatelaka kolongono ya nzoto, kasi bokengeli ya RCGP RSC eza mpenza yango moko.
The RCGP RSC, by extending its established work, will provide virological and serological surveillance to monitor the temporal and geographical distribution of COVID-19 infection in the community, and assess the effectiveness of the containment strategy.
RCGP RSC, mpe bato nyonso oyo basalaka na bango, ekokengela makambo ya virisi mpe ya serologie mpo na kolandela ndenge COVID-19 ezozwa bato ya mboka, mpe kotalela bokasi ya mayele basaleli mpo na kokanga yango nzela epanzana te.
We would not be working in isolation on this research.
Tokoki te kosala biso moko na bolukiluki oyo.
We will share the protocol with UK colleagues and the I-MOVE consortium who have recently obtained EU Horizon 2020 funding from the stream “Advancing knowledge for the clinical and public health response to the novel coronavirus epidemic”.
Tokokabola malako wana na banginga ya Royaume-Uni mpe lisanga I-MOVE oyo ezwi kala mingi te mosolo na EU Horizon 2020 mpo na “Boyebi mingi mpo na baekzame mpe kolongono ya nzoto mpo na kobundisa maladi mabe ya sika ya coronavirisi”.
It is anticipated that great efficiencies in project management will result through this collaboration than that obtained from countries acting alone.
Tokanisi ete kolandela misala oyo ekolonga mingi mpe ekosalema na nzela ya boyokani oyo koleka oyo euti na mikili oyo bazosala bango moko.
The aim of this study is to identify whether there is undetected community transmission of COVID-19, estimate population susceptibility, and monitor the temporal and geographical distribution of COVID-19 infection in the community.
Mokano ya bolukiluki oyo eza ya koyeba soki eza na lolenge moko oyo COVID-19 ezopesama oyo toyebi nanu te, koyeba ndenge bato bakoki kobundisa yango, mpe kolandela ndenge bato bazali kozwa maladi ya COVID-19.
The objectives of this study are as follows:
Mikano ya bolukiluki oyo yango oyo:
To monitor the burden of suspected COVID-19 activity in the community through primary care surveillance and clinical coding of possible COVID-19 cases referred into the containment pathway
Mpo na kolandela bokasi ya COVID-19 na mboka na nzela ya bokengeli ya premiers soins mpe kolandela bansango ya maladi ya bato oyo mbala mosusu baza na COVID-19 oyo tolobeli na makambo ya kosala mpo na kokanga yango nzela
To provide virological evidence on the presence and extent of undetected community transmission of COVID-19 and monitor positivity rates among individuals presenting ILI or acute respiratory tract infections to primary care
Mpo na kopesa bilembo ya kozala ya virisi oyo mpe degre oyo COVID-19 ezopesama na bato kozanga koyeba mpe kolandela taux ya malamu na kati ya bato oyo baza na bilembo ya maladi makasi ya ILI to maladi makasi ya nzela ya kopema ya nse na premiers soins
To estimate baseline susceptibility to COVID-19 in the community and estimate both symptomatic and asymptomatic exposure rates in the population through seroprevalence monitoring
Mpo na koyeba likoki ya kozwa maladi ya COVID-19 na bato ya mboka mpe koyeba taux ya bato baza na bilembo mpe oyo baza na bilembo na kati ya bato na nzela ya kolandela bansango ya bato
To pilot implementation of a scheme for collection of convalescent sera with antibody profiles among recovered cases of COVID-19 discharged to the community
Mpo na kolandela mayele ya kosangisa bansango ya bato bazobika na sera oyo baza na ba anticorps na kati ya bato oyo babika na COVID-19 oyo babima lopitalo na mboka